Last update 04 Jun 2026

SHR-2173

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Anti-IFNAR1/ TACI fusion protein(Jiangsu Hengrui Pharmaceutical), SHR-2173
Target
IFNAR-1 x TACI
Action
antagonists, inhibitors
Mechanism
IFNAR-1 antagonists(Interferon-alpha/beta receptor alpha chain antagonists), TNFRSF13B inhibitors(Tumor necrosis factor receptor superfamily member 13B inhibitors)
Therapeutic Areas
Immune System DiseasesSkin and Musculoskeletal DiseasesUrogenital Diseases+ [4]
Active Indication
Myasthenia GravisGlomerulonephritis, IGAIdiopathic Membranous Glomerulonephritis+ [4]
Inactive Indication-
Originator Organization
Guangdong Hengrui Pharmaceutical Co., Ltd.Guangdong Hengrui Pharmaceutical Co., Ltd.
Active Organization
Guangdong Hengrui Pharmaceutical Co., Ltd.Guangdong Hengrui Pharmaceutical Co., Ltd.Jiangsu Hengrui Pharmaceutical Group Co. Ltd.Jiangsu Hengrui Pharmaceutical Group Co. Ltd.Atridia Pty Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

9
Clinical Trials associated with SHR-2173
NCT07622342
/ Not yet recruitingPhase 2
A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of SHR-2173 in Patients With Generalized Myasthenia Gravis
NCT07299422
/ RecruitingPhase 2
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Systemic Lupus Erythematosus
NCT07354932
/ RecruitingPhase 2
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Primary IgA Nephropathy
100 Clinical Results associated with SHR-2173
Login to view more data
100 Translational Medicine associated with SHR-2173
Login to view more data
100 Patents (Medical) associated with SHR-2173
Login to view more data
100 Deals associated with SHR-2173
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myasthenia GravisPhase 2
China
Guangdong Hengrui Pharmaceutical Co., Ltd.Guangdong Hengrui Pharmaceutical Co., Ltd.
21 May 2026
Glomerulonephritis, IGAPhase 2
China
Guangdong Hengrui Pharmaceutical Co., Ltd.Guangdong Hengrui Pharmaceutical Co., Ltd.
09 Mar 2026
Idiopathic Membranous GlomerulonephritisPhase 2
China
Guangdong Hengrui Pharmaceutical Co., Ltd.Guangdong Hengrui Pharmaceutical Co., Ltd.
31 Dec 2025
Lupus NephritisPhase 2
China
Guangdong Hengrui Pharmaceutical Co., Ltd.Guangdong Hengrui Pharmaceutical Co., Ltd.
22 Nov 2025
Purpura, Thrombocytopenic, IdiopathicPhase 1
China
Guangdong Hengrui Pharmaceutical Co., Ltd.Guangdong Hengrui Pharmaceutical Co., Ltd.
12 Nov 2025
Autoimmune DiseasesPreclinical
China
Jiangsu Hengrui Pharmaceutical Group Co. Ltd.Jiangsu Hengrui Pharmaceutical Group Co. Ltd.
15 May 2025
InflammationPreclinical
China
Jiangsu Hengrui Pharmaceutical Group Co. Ltd.Jiangsu Hengrui Pharmaceutical Group Co. Ltd.
15 May 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free